2012 EDUCATIONAL BOOK - American Society of Clinical Oncology

IMAGING BIOMARKERS IN RENAL CANCER
Authors’ Disclosures of Potential Conflicts of Interest
Author
Employment or
Leadership
Positions
Consultant or
Advisory Role
Walter M. Stadler UpToDate AVEO; Caremark;
Genentech;
Millennium;
Novartis; Pfizer
Stock
Ownership Honoraria
Abbott
Laboratories (I)
1. Moertel CG, Hanley JA. The effect of measuring error on the results of
therapeutic trials in advanced cancer. Cancer. 1976;38:388-394.
2. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to
evaluate the response to treatment in solid tumors. European Organization
for Research and Treatment of Cancer, National Cancer Institute of the
United States, National Cancer Institute of Canada. J Natl Cancer Inst.
2000;92:205-216.
3. Oxnard GR, Zhao B, Sima CS, et al. Variability of lung tumor measurements
on repeat computed tomography scans taken within 15 minutes. J Clin
Oncol. 2011;29:3114-3119.
4. Halabi S, Rini BI, Stadler WM, et al: Use of progression-free survival
(PFS) to predict overall survival (OS) in patients with metastatic renal cell
carcinoma. J Clin Oncol. 2010;28;15s (suppl; abstract 4525).
5. Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of
immune therapy activity in solid tumors: immune-related response criteria.
Clin Cancer Res. 2009;15:7412-7420.
6. Karrison TG, Maitland ML, Stadler WM, et al. Design of phase II cancer
trials using a continuous endpoint of change in tumor size: application to a
study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer
Inst. 2007;99:1455-1461.
7. Sharma MR, Karrison TG, Jin Y, et al. Resampling phase III data to
assess phase II trial designs and endpoints. Clin Cancer Res. Epub 2012 Jan
27.
8. Zhao B, Oxnard GR, Moskowitz CS, et al. A pilot study of volume
measurement as a method of tumor response evaluation to aid biomarker
development. Clin Cancer Res. 2010;16:4647-4653.
9. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed
REFERENCES
Bayer/Onyx;
Clinical Care
Options; CME
Innovations;
Imedex; Pfizer;
Research-to-
Practice
Research
Funding
Active Biotech;
Bayer;
Boehringer
Ingelheim;
Bristol-Myers
Squibb;
Genentech;
GlaxoSmithKline;
ImClone
Systems; Infinity;
Lilly; Medarex;
Medivation;
Millennium;
Novartis; Pfizer;
Solvay; Takeda
Expert
Testimony
Other
Remuneration
tomography and positron emission tomography in patients with metastatic
gastrointestinal stromal tumor treated at a single institution with imatinib
mesylate: proposal of new computed tomography response criteria. J Clin
Oncol. 2007;25:1753-1759.
10. Krajewski KM, Guo M, Van den Abbeele AD, et al. Comparison of four
early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage,
computed tomography tumor density, Choi criteria) in assessing outcome to
vascular endothelial growth factor-targeted therapy in patients with advanced
renal cell carcinoma. Eur Urol. 2011;59:856-862.
11. Flaherty KT, Rosen MA, Heitjan DF, et al. Pilot study of DCE-MRI to
predict progression-free survival with sorafenib therapy in renal cell carcinoma.
Cancer Biol Ther. 2008;7:496-501.
12. Hahn OM, Yang C, Medved M, et al. Dynamic contrast-enhanced
magnetic resonance imaging pharmacodynamic biomarker study of sorafenib
in metastatic renal carcinoma. J Clin Oncol. 2008;26:4572-4578.
13. Sohaib SA, Cook G, Allen SD, et al. Comparison of whole-body MRI and
bone scintigraphy in the detection of bone metastases in renal cancer. Br J
Radiol. 2009;82:632-639.
14. Majhail NS, Urbain JL, Albani JM, et al. F-18 fluorodeoxyglucose
positron emission tomography in the evaluation of distant metastases from
renal cell carcinoma. J Clin Oncol. 2003;21:3995-4000.
15. Thomas GV, Tran C, Mellinghoff IK, et al. Hypoxia-inducible factor
determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med.
2006;12:122-127.
16. Chen JL, Appelbaum DE, Kocherginsky M, et al. FDG-PET as a
predictive marker for therapy with everolimus in metastatic renal cell cancer.
J Clin Oncol. 2011;29 (suppl; abstr e1504).
287